Skip to content
Use caution Drug recall · FDA · Published June 30, 2015

Hospira Ketorolac Injection Recall: Crystallization Hazard

Hospira recalls specific lots of Ketorolac Tromethamine Injection due to crystallization. Check your NDC and lot numbers for details on affected vials.

🇺🇸 FDA recall #D-1241-2015DrugHospira ›
Take action

Contact the company

Recalling firmHospira Inc.600 N Field Dr · Lake Forest, IL 60045-4835
✎ GovInfoNow plain-language explainer

What happened, in plain English

Hospira Inc. is recalling KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose Vials because the solution may contain crystallization identified as calcium salt of Ketorolac. This defect affects vials labeled under both Hospira and NOVAPLUS brands distributed nationwide and internationally. The record does not specify a remedy or consumer action steps. Read more at govinfonow.com/recall/44110-hospira-inc-recalls-ketorolac-tromethamine-inj-usp-30-mg-30.

Source Summary by GovInfoNow · govinfonow.com/recall/44110-hospira-inc-recalls-ketorolac-tromethamine-inj-usp-30-mg-30 · Updated October 12, 2026 · FDA enforcement record: FDA #D-1241-2015

Cite this page

“Hospira Ketorolac Injection Recall: Crystallization Hazard.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/44110-hospira-inc-recalls-ketorolac-tromethamine-inj-usp-30-mg-30. Based on FDA recall #D-1241-2015 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1241-2015%22&limit=1).

Why it’s dangerous

The hazard is the presence of crystallization, specifically identified as calcium salt of Ketorolac, within the injection solution. While the record does not detail specific injuries, administering medication with visible crystals can potentially compromise drug efficacy or cause adverse reactions at the injection site.

Who’s affected

Healthcare providers and patients who received KETOROLAC Tromethamine Injection from the specific lots listed in the recall notice. Individuals using these vials for intravenous (I.V.) or intramuscular (I.M.) administration are at risk of receiving a product with crystallization.

How to tell if you have this one

Look for Single-dose Vials containing KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill. Check the label for NDC 0409-3795-01 (Hospira) or NDC 0409-3795-49 (NOVAPLUS). Affected lots include those with expiration dates ranging from July 2015 to October 2016, such as lot 31077DK (EXP 01JUL2015) and lot 39256DK (EXP 01MAR2016).

  • Brand
    Hospira
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Ongoing
  • Distribution
    Nationwide, Puerto Rico, Guam, Canada and Singapore
Recall numberProduct, codes & lotsQuantityNDC
D-1241-2015KETOROLAC Tromethamine Inj., USP, 30 mg (30 mg/mL), 1 mL Fill, Single-dose Vials, I.V/I.M. USE, Hospira, Inc., Lake Forest, IL 60045 --- NDC 0409-3795-01 --- Also labeled under NOVAPLUS label NDC 0409-3795-49; 31077DK, 31078DK, 31338DK, 31339DK, 31340DK, EXP 01JUL2015; 32068DK, 32069DK, EXP 01AUG2915; 33270DK, EXP 01SEP2015; 34084DK, 34085DK, 34161DK, 34162DK, 34298DK, 34299DK, 34300DK, EXP 01OCT2015; 35011DK, 35081DK, 35082DK, 35116DK, EXP 01NOV2015; 38139DK, 38140DK, 36144DK, EXP 01FEB2016; 39256DK, 39257DK, EXP 01MAR2016; 42210DK, 42227DK, EXP01JUN2016; 43017DK, 43116DK, 43117DK, 43292DK, 43293DK, EXP 01JUL2016; 45034DK, 45035DK, 45118DK, 45120DK, EXP 01SEP2016; 46310DK, 46311DK, EXP 01OCT2016 AND NOVAPLUS LOTS 32106DK, 32220DK, 32221DK, EXP 01AUG2015; 33235DK, 33236DK, EXP 01SEP2015; 34163DK, 34164DK, EXP 01OCT2015; 39263DK, 39264DK, EXP 01MAR201612,460,975 vials(Hospira label); 3,016,500 vials (NOVAPLUS label)0409-3793-19, 0409-3793-01, 0409-3793-25, 0409-3795-19, 0409-3795-01, 0409-3795-25, 0409-3796-19, 0409-3796-01, 0409-3796-25, 0409-3795-49
D-1242-2015KETOROLAC Tromethamine Inj., USP, 60 mg (30 mg/mL), 2 mL Fill Single-dose Vials, I.V/I.M. USE, Hospira, Inc., Lake Forest, IL 60045 --- NDC 0409-3796-01 ---- ALSO labeled under NOVAPLUS label NDC 0409-3796-49; 31075DK, 31076DK, EXP01JUL2015; 32345DK, 32368DK, EXP 01AUG2015; 33152DK, EXP 01SEP2015; 34538DK, EXP 01OCT2015; 37227DK, EXP 01JAN2016, 41525DK, 42255DK, EXP 01MAY2016; 46042DK, 46045DK, 46048DK, 46304DK, 46305DK, 46432DK, 46433DK, EXP 01OCT2016 AND NOVAPLUS LOT 31074DK, EXP 01JUL20155,214,900 vials (Hospira label); 250,600 vials (NOVAPLUS label)0409-3793-19, 0409-3793-01, 0409-3793-25, 0409-3795-19, 0409-3795-01, 0409-3795-25, 0409-3796-19, 0409-3796-01, 0409-3796-25, 0409-3796-49

Where it went and when

Where it was distributed

Distributed nationwide, and outside the U.S.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide, Puerto Rico, Guam, Canada and Singapore” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide, and outside the U.S.

Recall timeline

FDA published this recall 22 days after the firm started it.

1. Firm started the recall: Jun 30, 201512. FDA classified it Class II: Jul 15, 201523. Published in FDA’s Enforcement Report: Jul 22, 201532015
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1241-2015 (June 30, 2015) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1241-2015 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA